Download Free Cardiovascular Therapeutics Book in PDF and EPUB Free Download. You can read online Cardiovascular Therapeutics and write the review.

Manage cardiovascular problems more effectively with the most comprehensive resource available! A trusted companion to Braunwald's Heart Disease, Cardiovascular Therapeutics, 4th Edition addresses pharmacological, interventional, and surgical management approaches for each type of cardiovascular disease. This practical and clinically focused cardiology reference offers a balanced, complete approach to all of the usual and unusual areas of cardiovascular disease and specific therapies in one concise volume, equipping you to make the best choices for every patient. Consult this title on your favorite e-reader with intuitive search tools and adjustable font sizes. Elsevier eBooks provide instant portable access to your entire library, no matter what device you're using or where you're located. Understand current approaches to treating and managing cardiovascular patients for long-term health, for complex problems, and for unusual cardiac events. Benefit from the substantial experience of Elliott M. Antman, MD, Marc S. Sabatine, MD, and a host of other respected authorities, who provide practical, evidence-based rationales for all of today's clinical therapies. Expand your knowledge beyond pharmacologic interventions with complete coverage of the most effective interventional and device therapies being used today. Easily reference Braunwald's Heart Disease, 9th Edition for further information on topics of interest. Make the best use of the latest genetic and molecular therapies as well as advanced therapies for heart failure. Cut right to the answers you need with an enhanced focus on clinically relevant information and a decreased emphasis on pathophysiology. Stay current with ACC/AHA/ESC guidelines and the best ways to implement them in clinical practice. Get an enhanced visual perspective with an all-new, full-color design throughout.
For physicians, surgeons, and scientists working on cardiovascular disorders, Applications of Biotechnology in Cardiovascular Therapeutics serves as an invaluable reference by collecting the essential writings of Dr. Kewal K. Jain on the topics of biotechnology as they relate to cardiovascular disease. This thorough volume includes such subjects as biotechnology and therapeutic delivery to the cardiovascular system, cell-selective targeted drug delivery, cell and gene therapies, including antisense and RNA interference, cutting-edge gene therapy approaches, as well as personalized cardiology as a way of integrating new technologies into the selection of the best possible treatment for an individual patient. Selected references from recent literature are collected for each chapter, and the text is supplemented by a variety of useful tables and figures. Comprehensive and up-to-date, Applications of Biotechnology in Cardiovascular Therapeutics will be tremendously useful for those working in life sciences and the pharmaceutical sciences, and the inclusion of some basics of cardiovascular diseases will greatly benefit nonmedical readers as well.
This companion to Braunwald's Heart Disease equips you with all of today's most effective therapeutic guidelines and management solutions for the full range of heart disease patients. It reflects the most recent standards for drug management as well as the latest in new technologies. Reorganized to mirror your changing practice, each cardiovascular-problem-based section offers a chapter on pharmacologic treatment (with a minimum of pathophysiology)...a chapter on catheter-based or minimally invasive interventions...and a discussion of surgical options. You'll also find a brand-new chapter on gene therapy and stem cell therapy, plus new chapters on many other rapidly developing areas of practice. The result is an outstanding single-volume source for state-of-the-art, clinically oriented guidance on both common and unusual areas of cardiovascular treatment. Facilitates the decision-making process clinicians face when choosing among various cardiovascular therapeutic options. covers the latest concepts in pathophysiology, evaluation, and management of patients with cardiovascular disorders Addresses pharmacological, interventional, and surgical management approaches for each type of cardiovascular disease, putting advice on the full range of therapeutic options at your disposal. Keeps you current with brand-new chapters on gene therapy and stem cell therapy * unstable and chronic stable angina * management of unstable angina and non-ST-elevation myocardial infarction * devices for heart failure and arrhythmias * prevention of ischemic disease * the regulatory approval process for new cardiovascular drugs and devices * and more. Delivers a fully revised section on "Heart Failure" that explores cardiac resynchronization therapy, surgical interventions, ambulatory management, hospital management, and cardiac transplantation and circulatory support devices. Offers a completely updated section on "Other Cardiovascular Conditions" that addresses issues such as pharmacologic treatment of cardiovascular disease during pregnancy * care for adults with congenital heart disease * treatment of primary pulmonary hypertension * prevention and treatment of infective endocarditis * treatment of pericardial disease * and rehabilitation of the patient with cardiovascular disease. Reflects a new emphasis on the role of diet and exercise in the management of cardiovascular problems in conformity with ACC/AHA/ESC guidelines.
A critically acclaimed classic reference now in its third edition, Cardiovascular Pharmacotherapeutics provides current information regarding the contemporary use of all available cardiovascular medications for adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds that are under development and may emerge as the cardiac therapies of the future. This edition also addresses special considerations for drug therapy use in the elderly, during pregnancy, and in those with hepatic or renal disease. A generous assortment of tables, figures, and appendices guides readers in their investigations of each drug group and various disease states.
Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. • Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases • Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology • Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases • Uses case presentations and study questions to enhance understanding of the material • Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues
The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.
Scientific evidence from both preclinical, and clinical studies indicates that male and female patients with cardiovascular disease (CVD) exhibit different clinical, epidemiological, and pathological characteristics, with sexually dimorphic biological factors exhibiting a significant influence in the development of CVD and therapeutic responses. Sexually dimorphic physiology that contributes to sex differences in cardiovascular therapeutic responses may include; immune responses, cardio-renal health, the blood-brain barrier, coronary atherosclerosis pathology, complications of COVID-19 infections, and the interplay between psychological factors and sedentarism. Furthermore, current knowledge indicates the role of hormonal regulation has a significant impact in sex-specific differences across the clinical cardiology field. The National Institute of Health (NIH) previously adopted a policy to encourage researchers to consider sex as a biological variable (SABV) as well as Sex and Gender Equity in Research (SAGER). In order to promote sexual dimorphic cardiovascular therapeutic development, we have organized this special topic “Sex Differences and Cardiovascular Therapeutics” to provide a scientific forum for cardiovascular scientists and clinicians to present their newest findings in characterizing sex differences in cardiovascular therapeutics. Potential areas of research within this collection may include, but are not limited to: 1) Different outcomes and responses to drug treatment in cardiovascular disease between male and female. 2) Mechanisms of sexual dimorphic response and outcomes related to drug treatment of cardiovascular disease. 3) Sex hormones and their receptors in cardiovascular function in animal studies and clinical therapeutic applications. 4) Gender affirming hormone therapy and cardiovascular function. 5) Regulatory guidance for cardiovascular therapeutics in relation to sex-specific differences.